The Prognostic Implication of the Basal-Like (Cyclin E high/p27low/p53 +/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer

Cancer Research

Volumn 64, Issue 3, 2004, Pages 830-835

  Foulkes, William D ^a,b,g   Brunet, Jean Sébastien ^a,c   Stefansson, Ingunn M ^d   Straume, Oddbjørn ^d   Chappuis, Pierre O ^b   Bégin, Louis R ^a   Hamel, Nancy ^a,b   Goffin, John R ^a   Wong, Nora ^a   Trudel, Michel ^a   Kapusta, Linda ^e   Porter, Peggy ^f   Akslen, Lars A ^d  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Algorithme Pharma   (Canada)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF WASHINGTON   (United States)

^g MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROTEIN P27; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BASAL CELL; BREAST CANCER; BREAST EPITHELIUM; CANCER GRADING; CELL ENCAPSULATION; CELL PROLIFERATION; FEMALE; GENE MUTATION; GERM LINE; GLOMERULOID MICROVASCULAR PROLIFERATION; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROVASCULATURE; MULTIVARIATE ANALYSIS; ONCOGENE; OUTCOMES RESEARCH; PARSIMONY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENES, BRCA1; HUMANS; KERATINS; MIDDLE AGED; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 10744223743     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2970     Document Type: Article

References (26)

1. Lakhani, S. R., van de Vijver, M. J., Jacquemier, J., Anderson, T. J., Osin, P. P., McGuffog, L., and Easton, D. F. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol., 20: 2310-2318, 2002.
2. Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Kallioniemi, O. P., Wilfond, B., Borg, A., and Trent, J. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med., 344: 539-548, 2001.
3. Chappuis, P. O., Nethercot, V., and Foulkes, W. D. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin. Surg. Oncol., 18: 287-295, 2000.
4. Foulkes, W. D., Metcalfe, K., Hanna, W., Lynch, H. T., Ghadirian, P., Tung, N., Olopade, O., Weber, B., McLennan, J., Olivotto, I. A., Sun, P., Chappuis, P. O., Bégin, L. R., Brunet, J.-S., and Narod, S. A. Disruption of the expected positive correlation between tumor size and nodal status in BRCA1-related breast cancer. Cancer (Phila.), 98: 1569-1577, 2003.
5. Chappuis, P. O., Kapusta, L., Bégin, L. R., Wong, N., Brunet, J. S., Narod, S. A., Slingerland, J., and Foulkes, W. D. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J. Clin. Oncol., 18: 4045-4052, 2000.
6. Greenblatt, M. S., Chappuis, P. O., Bond, J. P., Hamel, N., and Foulkes, W. D. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res., 61: 4092-4097, 2001.
7. Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., Demeter, J., Perou, C. M., Lonning, P. E., Brown, P. O., Borresen-Dale, A. L., and Botstein, D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA, 100: 8418-8423, 2003.
8. Foulkes, W. D., Stefansson, I. M., Chappuis, P. O., Begin, L. R., Goffin, J. R., Wong, N., Trudel, M., and Akslen, L. A. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst. (Bethesda), 95: 1482-1485, 2003.
9. Goffin, J. R., Straume, O., Chappuis, P. O., Brunet, J-S., Bégin, L. R., Hamel, N., Wong, N., Akslen, L. A., and Foulkes, W. D. Glomeruloid Microvascular Proliferation is associated with p53 overexpression, germ-line BRCA1 mutations and an adverse outcome following breast cancer. Br. J. Cancer, 89: 1031-1034, 2003.
10. Robson, M. E., Boyd, J., Borgen, P. I., and Cody, H. S., III. Hereditary breast cancer. Curr. Probl. Surg., 38: 387-480, 2001.
11. Moll, R., Franke, W. W., Schiller, D. L., Geiger, B., and Krepler, R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell, 31: 11-24, 1982.
12. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
13. Straume, O., Chappuis, P. O., Salvesen, H. B., Halvorsen, O. J., Haukaas, S. A., Goffin, J. R., Begin, L. R., Foulkes, W. D., and Akslen, L. A. Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res., 62: 6808-6811, 2002.
14. Korsching, E., Packeisen, J., Agelopoulos, K., Eisenacher, M., Voss, R., Isola, J., van Diest, P. J., Brandt, B., Boecker, W., and Buerger, H. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab. Investig., 82: 1525-1533, 2002.
15. Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenshikov, A., Williams, C, Zhu, S. X., Lonning, P. E., Borresen-Dale, A. L., Brown, P. O., and Botstein, D. Molecular portraits of human breast tumours. Nature (Lond.), 406: 747-752, 2000.
16. Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Thorsen, T., Quist, H., Matese, J. C., Brown, P. O., Botstein, D., Lonning, P. E., and Borresen-Dale, A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA, 98: 10869-10874, 2001.
17. Van't Veer, L. J., Dai, H. Y., van de Vijver, M. J., He, Y. D. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., and Friend, S. H. Gene expression profiling predicts clinical outcome of breast cancer. Nature (Lond.), 415: 530-536, 2002.
18. Signoretti, S., Di Marcotullio, L., Richardson, A., Ramaswamy, S., Isaac, B., Rue, M., Monti, F., Loda, M., and Pagano, M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Investig., 110: 633-641, 2002.
19. Carrano, A. C., Eytan, E., Hershko, A., and Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell. Biol., 1: 193-199, 1999.
20. Kauraniemi, P., Hedenfalk, I., Persson, K., Duggan, D. J., Tanner, M., Johannsson, O., Olsson, H., Trent, J. M., Isola, J., and Borg, A. MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res., 60: 5323-5328, 2000.
21. Berns, E. M., Dirkzwager-Kiel, M. J., Kuenen-Boumeester, V., Timmermans, M., Verhoog, L. C., van den Ouweland, A. M., Meijer-Heijboer, H., Klijn, J. G., and van der Kwast, T. H. Androgen pathway dysregulation in BRCA1-mutated breast tumors. Breast Cancer Res. Treat., 79: 121-127, 2003.
22. Dairkee, S. H., Mayall, B. H., Smith, H. S., and Hackett, A. J. Monoclonal marker that predicts early recurrence of breast-cancer. Lancet, 1: 514, 1987.
23. Malzahn, K., Mitze, M., Thoenes, M., and Moll, R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch., 433: 119-129, 1998.
24. Tsuda, H., Takarabe, T., Hasegawa, F., Fukutomi, T., and Hirohashi, S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am. J. Surg. Pathol., 24: 197-202, 2000.
25. van de Rijn, M., Perou, C. M., Tibshirani, R., Haas, P., Kallioniemi, C., Kononen, J., Torhorst, J., Sauter, G., Zuber, M., Kochli, O. R., Mross, F., Dieterich, H., Seitz, R., Ross, D., Botstein, D., and Brown, P. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol., 161: 1991-1996, 2002.
26. Takei, H., Iino, Y., Horiguchi, J., Maemura, M., Oyama, T., Yokoe, T., and Morishita, Y. Low and high molecular weight cytokeratins in invasive breast carcinoma. Oncol. Rep., 4: 33-38, 1997.